Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Conus

Showing results (261-270 of 289) with videos related to

Pageof 29
Sort By:
Molecular Psychiatry|September 17, 2025
Dietary caffeine to assess CYP1A2 activity, tailor clozapine doses, and predict treatment response: genetic, epigenetic and clinical analysesNermine Laaboub, Frederik Vandenberghe, Nicolas Ansermot, et al.
Bipolar Disorders|September 4, 2019
An International Society of Bipolar Disorders task force report: Precursors and prodromes of bipolar disorderGianni L Faedda, Ross J Baldessarini, Ciro Marangoni, et al.
Biological Psychiatry|May 21, 2018
Quantifying the Effects of 16p11.2 Copy Number Variants on Brain Structure: A Multisite Genetic-First StudySandra Martin-Brevet, Borja Rodríguez-Herreros, Jared A Nielsen, et al.
Journal of Clinical Medicine|July 29, 2023
Improving Pathways to Care for Patients at High Psychosis Risk in Switzerland: PsyYoung Study ProtocolCaroline Conchon, Elodie Sprüngli-Toffel, Luis Alameda, et al.
Spanish Journal of Psychiatry and Mental Health|September 20, 2024
Individualized pretest risk estimates to guide treatment decisions in patients with clinical high risk for psychotic disordersElodie Sprüngli-Toffel, Erich Studerus, Logos Curtis, et al.
The Lancet Regional Health. Europe|August 30, 2022
The psychosis metabolic risk calculator (PsyMetRiC) for young people with psychosis: International external validation and site-specific recalibration in two independent European samplesBenjamin I Perry, Frederik Vandenberghe, Nathalia Garrido-Torres, et al.
Biological Psychiatry|January 9, 2016
The Number of Genomic Copies at the 16p11.2 Locus Modulates Language, Verbal Memory, and InhibitionLoyse Hippolyte, Anne M Maillard, Borja Rodriguez-Herreros, et al.
Bjpsych Open|January 5, 2024
Proxy measures for the assessment of psychotic and affective symptoms in studies using electronic health recordsÁlvaro López-Díaz, Fernanda Jazmín Palermo-Zeballos, Luis Gutierrez-Rojas, et al.
Journal of Medical Genetics|October 12, 2012
A 600 kb deletion syndrome at 16p11.2 leads to energy imbalance and neuropsychiatric disordersFlore Zufferey, Elliott H Sherr, Noam D Beckmann, et al.
Schizophrenia Research|October 15, 2022
Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortiumSophie E Smart, Deborah Agbedjro, Antonio F Pardiñas, et al.
Pageof 29

Showing results (261-270 of 289) with videos related to

Sort By:
Pageof 29
Molecular Psychiatry|September 17, 2025
Dietary caffeine to assess CYP1A2 activity, tailor clozapine doses, and predict treatment response: genetic, epigenetic and clinical analysesNermine Laaboub, Frederik Vandenberghe, Nicolas Ansermot, et al.
Bipolar Disorders|September 4, 2019
An International Society of Bipolar Disorders task force report: Precursors and prodromes of bipolar disorderGianni L Faedda, Ross J Baldessarini, Ciro Marangoni, et al.
Biological Psychiatry|May 21, 2018
Quantifying the Effects of 16p11.2 Copy Number Variants on Brain Structure: A Multisite Genetic-First StudySandra Martin-Brevet, Borja Rodríguez-Herreros, Jared A Nielsen, et al.
Journal of Clinical Medicine|July 29, 2023
Improving Pathways to Care for Patients at High Psychosis Risk in Switzerland: PsyYoung Study ProtocolCaroline Conchon, Elodie Sprüngli-Toffel, Luis Alameda, et al.
Spanish Journal of Psychiatry and Mental Health|September 20, 2024
Individualized pretest risk estimates to guide treatment decisions in patients with clinical high risk for psychotic disordersElodie Sprüngli-Toffel, Erich Studerus, Logos Curtis, et al.
The Lancet Regional Health. Europe|August 30, 2022
The psychosis metabolic risk calculator (PsyMetRiC) for young people with psychosis: International external validation and site-specific recalibration in two independent European samplesBenjamin I Perry, Frederik Vandenberghe, Nathalia Garrido-Torres, et al.
Biological Psychiatry|January 9, 2016
The Number of Genomic Copies at the 16p11.2 Locus Modulates Language, Verbal Memory, and InhibitionLoyse Hippolyte, Anne M Maillard, Borja Rodriguez-Herreros, et al.
Bjpsych Open|January 5, 2024
Proxy measures for the assessment of psychotic and affective symptoms in studies using electronic health recordsÁlvaro López-Díaz, Fernanda Jazmín Palermo-Zeballos, Luis Gutierrez-Rojas, et al.
Journal of Medical Genetics|October 12, 2012
A 600 kb deletion syndrome at 16p11.2 leads to energy imbalance and neuropsychiatric disordersFlore Zufferey, Elliott H Sherr, Noam D Beckmann, et al.
Schizophrenia Research|October 15, 2022
Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortiumSophie E Smart, Deborah Agbedjro, Antonio F Pardiñas, et al.
Pageof 29